Journal Article
. 2005 Sep;23(29).
doi: 10.1200/JCO.2005.02.0818.

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

Luca Gianni 1 Milvia Zambetti  Kim Clark  Joffre Baker  Maureen Cronin  Jenny Wu  Gabriella Mariani  Jaime Rodriguez  Marialuisa Carcangiu  Drew Watson  Pinuccia Valagussa  Roman Rouzier  W Fraser Symmans  Jeffrey S Ross  Gabriel N Hortobagyi  Lajos Pusztai  Steven Shak  
  • PMID: 16145055
  •     141 citations


Purpose: We sought to identify gene expression markers that predict the likelihood of chemotherapy response. We also tested whether chemotherapy response is correlated with the 21-gene Recurrence Score assay that quantifies recurrence risk.

Methods: Patients with locally advanced breast cancer received neoadjuvant paclitaxel and doxorubicin. RNA was extracted from the pretreatment formalin-fixed paraffin-embedded core biopsies. The expression of 384 genes was quantified using reverse transcriptase polymerase chain reaction and correlated with pathologic complete response (pCR). The performance of genes predicting for pCR was tested in patients from an independent neoadjuvant study where gene expression was obtained using DNA microarrays.

Results: Of 89 assessable patients (mean age, 49.9 years; mean tumor size, 6.4 cm), 11 (12%) had a pCR. Eighty-six genes correlated with pCR (unadjusted P < .05); pCR was more likely with higher expression of proliferation-related genes and immune-related genes, and with lower expression of estrogen receptor (ER) -related genes. In 82 independent patients treated with neoadjuvant paclitaxel and doxorubicin, DNA microarray data were available for 79 of the 86 genes. In univariate analysis, 24 genes correlated with pCR with P < .05 (false discovery, four genes) and 32 genes showed correlation with P < .1 (false discovery, eight genes). The Recurrence Score was positively associated with the likelihood of pCR (P = .005), suggesting that the patients who are at greatest recurrence risk are more likely to have chemotherapy benefit.

Conclusion: Quantitative expression of ER-related genes, proliferation genes, and immune-related genes are strong predictors of pCR in women with locally advanced breast cancer receiving neoadjuvant anthracyclines and paclitaxel.

American Society for Clinical Oncology 40th annual meeting, New Orleans, LA, 5-8 June 2004: breast cancer highlights.
Mark L Sundermeyer, Lori J Goldstein.
Breast Cancer Res, 2004 Nov 13; 6(6). PMID: 15535859    Free PMC article.
Gene expression profiling of primary breast cancer.
Roman Rouzier, Peter Wagner, Paolo Morandi, Lajos Pusztai.
Curr Oncol Rep, 2004 Dec 22; 7(1). PMID: 15610685
A systems approach to clinical oncology: focus on breast cancer.
Mark Abramovitz, Brian Leyland-Jones.
Proteome Sci, 2006 Apr 06; 4. PMID: 16595007    Free PMC article.
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
Donald A Berry, Constance Cirrincione, +9 authors, Eric P Winer.
JAMA, 2006 Apr 13; 295(14). PMID: 16609087    Free PMC article.
Highly Cited.
Molecular biology of breast cancer.
Miguel Martín.
Clin Transl Oncol, 2006 Apr 25; 8(1). PMID: 16632434
Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review.
Manfred Dietel, Christine Sers.
Virchows Arch, 2006 Jun 01; 448(6). PMID: 16736190
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
Laurel A Habel, Steven Shak, +12 authors, Charles P Quesenberry.
Breast Cancer Res, 2006 Jun 02; 8(3). PMID: 16737553    Free PMC article.
Highly Cited.
Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy.
Fabrice Andre, Lajos Pusztai.
Pharm Res, 2006 Aug 15; 23(9). PMID: 16906452
Guidelines from the European Society of Breast Imaging for diagnostic interventional breast procedures.
Matthew Wallis, Anne Tardivon, +3 authors, European Society of Breast Imaging.
Eur Radiol, 2006 Oct 03; 17(2). PMID: 17013595
HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?
A Vincent-Salomon, J-Y Pierga, +8 authors, X Sastre-Garau.
Br J Cancer, 2007 Jan 31; 96(4). PMID: 17262082    Free PMC article.
A new molecular breast cancer subclass defined from a large scale real-time quantitative RT-PCR study.
Maïa Chanrion, Hélène Fontaine, +5 authors, Jean-Marie Darbon.
BMC Cancer, 2007 Mar 07; 7. PMID: 17338809    Free PMC article.
Molecular profiling in breast cancer.
Shannon R Morris, Lisa A Carey.
Rev Endocr Metab Disord, 2007 Apr 28; 8(3). PMID: 17464566
Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.
Vincent Vuaroqueaux, Patrick Urban, +8 authors, Serenella Eppenberger-Castori.
Breast Cancer Res, 2007 May 31; 9(3). PMID: 17535433    Free PMC article.
Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer.
Erica L Mayer, Lisa A Carey, Harold J Burstein.
Breast Cancer Res, 2007 Sep 25; 9(5). PMID: 17888189    Free PMC article.
High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies.
M A Bollet, A Savignoni, +9 authors, A Vincent-Salomon.
Br J Cancer, 2008 Feb 07; 98(4). PMID: 18253121    Free PMC article.
Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses.
René Natowicz, Roberto Incitti, +7 authors, Roman Rouzier.
BMC Bioinformatics, 2008 Mar 28; 9. PMID: 18366635    Free PMC article.
Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer.
Brian M Nolen, Jeffrey R Marks, +5 authors, Anna E Lokshin.
Breast Cancer Res, 2008 May 14; 10(3). PMID: 18474099    Free PMC article.
Viability analysis and apoptosis induction of breast cancer cells in a microfluidic device: effect of cytostatic drugs.
Job Komen, Floor Wolbers, +3 authors, Albert van den Berg.
Biomed Microdevices, 2008 Jun 05; 10(5). PMID: 18523888    Free PMC article.
Preoperative systemic chemotherapy and pathologic assessment of response.
Lajos Pusztai.
Pathol Oncol Res, 2008 Jun 17; 14(2). PMID: 18553157
Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome.
G Somlo, P Chu, +5 authors, P Danenberg.
Ann Oncol, 2008 Jul 22; 19(11). PMID: 18641005    Free PMC article.
Over-expression of Skp2 is associated with resistance to preoperative doxorubicin-based chemotherapy in primary breast cancer.
Shirly Davidovich, Ofer Ben-Izhak, +2 authors, Dan D Hershko.
Breast Cancer Res, 2008 Jul 23; 10(4). PMID: 18644126    Free PMC article.
[Virtual microscopy in systems pathology].
N Grabe.
Pathologe, 2008 Sep 30; 29 Suppl 2. PMID: 18820917
Gene expression profiling of breast cancer.
Ting Bao, Nancy E Davidson.
Adv Surg, 2008 Oct 29; 42. PMID: 18953822    Free PMC article.
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer.
Pierre Farmer, Hervé Bonnefoi, +18 authors, Mauro Delorenzi.
Nat Med, 2009 Jan 06; 15(1). PMID: 19122658
Highly Cited.
Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.
Genet Med, 2009 Jan 07; 11(1). PMID: 19125125    Free PMC article.
Genomancy: predicting tumour response to cancer therapy based on the oracle of genetics.
P D Williams, J K Lee, D Theodorescu.
Curr Oncol, 2009 Feb 21; 16(1). PMID: 19229372    Free PMC article.
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.
Joseph A Sparano, Stacy Moulder, +16 authors, Said M Sebti.
Clin Cancer Res, 2009 Apr 09; 15(8). PMID: 19351752    Free PMC article.
Inhibition of RelB by 1,25-dihydroxyvitamin D3 promotes sensitivity of breast cancer cells to radiation.
Nora D Mineva, Xiaobo Wang, +4 authors, Gail E Sonenshein.
J Cell Physiol, 2009 Apr 18; 220(3). PMID: 19373868    Free PMC article.
Neoadjuvant chemotherapy for "triple negative" breast cancer: a review of current practice and future outlook.
Zeina Nahleh.
Med Oncol, 2009 Jun 11; 27(2). PMID: 19513864
Genomic predictors of outcome and treatment response in breast cancer.
Lara Dunn, Angela Demichele.
Mol Diagn Ther, 2009 Jun 23; 13(2). PMID: 19537843
Verification of a prolonged untreated natural history of breast cancer by the multigene assay.
Tadeja Urbas, Neal Agee, Marcia E Bouton, Ian K Komenaka.
Med Oncol, 2009 Jun 24; 27(3). PMID: 19548125
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.
Philippe L Bedard, Angelo Di Leo, Martine J Piccart-Gebhart.
Nat Rev Clin Oncol, 2009 Dec 10; 7(1). PMID: 19997076
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer.
G Munkácsy, R Abdul-Ghani, +5 authors, B Györffy.
Br J Cancer, 2009 Dec 17; 102(2). PMID: 20010949    Free PMC article.
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer.
Abigail S Caudle, Ana M Gonzalez-Angulo, +7 authors, Funda Meric-Bernstam.
J Clin Oncol, 2010 Mar 17; 28(11). PMID: 20231683    Free PMC article.
Review of the clinical studies using the 21-gene assay.
Catherine M Kelly, Ellen Warner, +2 authors, Kathleen I Pritchard.
Oncologist, 2010 Apr 28; 15(5). PMID: 20421266    Free PMC article.
Molecular markers to individualize adjuvant therapy for colon cancer.
Tara Gangadhar, Richard L Schilsky.
Nat Rev Clin Oncol, 2010 May 05; 7(6). PMID: 20440283
Molecular basis for therapy resistance.
Per E Lønning.
Mol Oncol, 2010 May 15; 4(3). PMID: 20466604    Free PMC article.
Quantitative expression profiling in formalin-fixed paraffin-embedded samples by affymetrix microarrays.
Diana Abdueva, Michele Wing, +2 authors, Elai Davicioni.
J Mol Diagn, 2010 Jun 05; 12(4). PMID: 20522636    Free PMC article.
Breast cancer, neoadjuvant chemotherapy and residual disease.
Mariana Chávez-MacGregor, Ana María González-Angulo.
Clin Transl Oncol, 2010 Jul 10; 12(7). PMID: 20615822
Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.
Adel Tabchy, Vicente Valero, +14 authors, Lajos Pusztai.
Clin Cancer Res, 2010 Sep 11; 16(21). PMID: 20829329    Free PMC article.
Molecular mechanisms of metastasis in breast cancer--clinical applications.
Michal Mego, Sendurai A Mani, Massimo Cristofanilli.
Nat Rev Clin Oncol, 2010 Oct 20; 7(12). PMID: 20956980
Molecular profiling contributes more than routine histology and immonohistochemistry to breast cancer diagnostics.
Christine Shiang, Lajos Pusztai.
Breast Cancer Res, 2011 Jan 05; 12 Suppl 4. PMID: 21172090    Free PMC article.
Unliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpoint.
Melanie M Badtke, Purevsuren Jambal, +4 authors, Britta M Jacobsen.
Breast Cancer Res Treat, 2011 Feb 23; 131(1). PMID: 21340479    Free PMC article.
Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?
Philippe L Bedard, Fatima Cardoso.
Nat Rev Clin Oncol, 2011 Mar 03; 8(5). PMID: 21364525
Immune parameters affecting the efficacy of chemotherapeutic regimens.
Laurence Zitvogel, Oliver Kepp, Guido Kroemer.
Nat Rev Clin Oncol, 2011 Mar 03; 8(3). PMID: 21364688
Highly Cited. Review.
Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy.
Carsten Denkert, Silvia Darb-Esfahani, +2 authors, Korinna Jöhrens.
Semin Immunopathol, 2011 Apr 19; 33(4). PMID: 21499853
Targeting the cell cycle in esophageal adenocarcinoma: an adjunct to anticancer treatment.
Martyn Dibb, Yeng S Ang.
World J Gastroenterol, 2011 May 07; 17(16). PMID: 21547123    Free PMC article.
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
Christos Hatzis, Lajos Pusztai, +27 authors, W Fraser Symmans.
JAMA, 2011 May 12; 305(18). PMID: 21558518    Free PMC article.
Highly Cited.
Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer.
Ruth Oratz, Benjamin Kim, +4 authors, Michael Broder.
J Oncol Pract, 2011 Jul 07; 7(2). PMID: 21731516    Free PMC article.
Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients.
Yang Xie, Guanghua Xiao, +11 authors, Ignacio I Wistuba.
Clin Cancer Res, 2011 Jul 12; 17(17). PMID: 21742808    Free PMC article.
Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction.
Pierre-Emmanuel Colombo, Fernanda Milanezi, Britta Weigelt, Jorge S Reis-Filho.
Breast Cancer Res, 2011 Jul 27; 13(3). PMID: 21787441    Free PMC article.
Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox.
Ling Yao, Yan Zhang, +2 authors, Lisa X Xu.
PLoS One, 2011 Sep 21; 6(9). PMID: 21931812    Free PMC article.
Practical implications of gene-expression-based assays for breast oncologists.
Aleix Prat, Matthew J Ellis, Charles M Perou.
Nat Rev Clin Oncol, 2011 Dec 07; 9(1). PMID: 22143140    Free PMC article.
Highly Cited. Review.
Early developments in gene-expression profiling of breast tumors: potential for increasing black-white patient disparities in breast cancer outcomes?
Donna H Odierna, Aimee Afable-Munsuz, +5 authors, Ninez A Ponce.
Per Med, 2011 Dec 23; 8(6). PMID: 22190978    Free PMC article.
Whole transcriptome RNA-Seq analysis of breast cancer recurrence risk using formalin-fixed paraffin-embedded tumor tissue.
Dominick Sinicropi, Kunbin Qu, +14 authors, Joffre Baker.
PLoS One, 2012 Jul 19; 7(7). PMID: 22808097    Free PMC article.
Understanding how breast cancer patients use risk information from genomic tests.
Jessica T DeFrank, Lisa A Carey, Noel T Brewer.
J Behav Med, 2012 Aug 11; 36(6). PMID: 22878783    Free PMC article.
Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer.
Zhi-Heng Huang, Xing-Song Tian, +4 authors, Ya-Jie Yang.
Exp Ther Med, 2012 Sep 13; 3(2). PMID: 22969891    Free PMC article.
17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy.
Wonshik Han, Jung Hoon Woo, +11 authors, Dong-Young Noh.
Exp Ther Med, 2012 Sep 15; 2(5). PMID: 22977578    Free PMC article.
Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer.
Antonia Sophie Wenners, Keyur Mehta, +16 authors, Maret Bauer.
PLoS One, 2012 Oct 12; 7(10). PMID: 23056218    Free PMC article.
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat.
Ont Health Technol Assess Ser, 2010 Jan 01; 10(23). PMID: 23074401    Free PMC article.
Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer.
Siwei Wei, Lingyan Liu, +8 authors, Daniel Raftery.
Mol Oncol, 2012 Nov 13; 7(3). PMID: 23142658    Free PMC article.
Barriers to the use of personalized medicine in breast cancer.
Christine B Weldon, Julia R Trosman, +2 authors, Julian C Schink.
J Oncol Pract, 2012 Nov 28; 8(4). PMID: 23180995    Free PMC article.
Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients.
Michael R Mallmann, Andrea Staratschek-Jox, +5 authors, Joachim L Schultze.
EPMA J, 2010 Sep 01; 1(3). PMID: 23199086    Free PMC article.
USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer.
Soley Bayraktar, Angelica M Gutierrez Barrera, +8 authors, Banu Arun.
Cancer J, 2013 Jan 23; 19(1). PMID: 23337751    Free PMC article.
Current approaches for neoadjuvant chemotherapy in breast cancer.
Roisin M Connolly, Vered Stearns.
Eur J Pharmacol, 2013 Apr 03; 717(1-3). PMID: 23545358    Free PMC article.
Role of dendritic cells in the regulation of antitumor immunity.
Nathalie Wathelet, Muriel Moser.
Oncoimmunology, 2013 Jun 05; 2(4). PMID: 23734333    Free PMC article.
Correlation between the molecular subtype of breast cancer and the in vitro adenosine triphosphate-based chemosensitivity assay.
Jina Chang, Anbok Lee, +3 authors, Byung-In Moon.
J Korean Surg Soc, 2013 Jun 07; 84(6). PMID: 23741688    Free PMC article.
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.
A Goldhirsch, E P Winer, +5 authors, Panel members.
Ann Oncol, 2013 Aug 07; 24(9). PMID: 23917950    Free PMC article.
Highly Cited.
Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.
Amylou C Dueck, Monica M Reinholz, +16 authors, Edith A Perez.
Clin Cancer Res, 2013 Aug 24; 19(20). PMID: 23965903    Free PMC article.
Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients.
A Sánchez-Muñoz, Y Plata-Fernández, +7 authors, P Sánchez-Rovira.
Clin Transl Oncol, 2013 Oct 03; 16(6). PMID: 24085576
Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer.
Takayuki Ueno, Norikazu Masuda, +12 authors, Masakazu Toi.
Int J Clin Oncol, 2013 Oct 09; 19(4). PMID: 24101215
The SmgGDS splice variant SmgGDS-558 is a key promoter of tumor growth and RhoA signaling in breast cancer.
Andrew D Hauser, Carmen Bergom, +5 authors, Carol L Williams.
Mol Cancer Res, 2013 Nov 08; 12(1). PMID: 24197117    Free PMC article.
Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival.
F Bertucci, N T Ueno, +16 authors, S J Van Laere.
Ann Oncol, 2013 Dec 05; 25(2). PMID: 24299959    Free PMC article.
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.
Yasmin Issa-Nummer, Silvia Darb-Esfahani, +18 authors, Carsten Denkert.
PLoS One, 2013 Dec 07; 8(12). PMID: 24312450    Free PMC article.
Magnetic resonance metabolic profiling of breast cancer tissue obtained with core needle biopsy for predicting pathologic response to neoadjuvant chemotherapy.
Ji Soo Choi, Hyeon-Man Baek, +5 authors, Youn Ki Nam.
PLoS One, 2013 Dec 25; 8(12). PMID: 24367616    Free PMC article.
Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients.
Anna Tessari, Dario Palmieri, Serena Di Cosimo.
Pharmgenomics Pers Med, 2014 Jan 10; 7. PMID: 24403841    Free PMC article.
Molecular tests as prognostic factors in breast cancer.
Marc J van de Vijver.
Virchows Arch, 2014 Feb 04; 464(3). PMID: 24487789
Genomic profiling in luminal breast cancer.
Oleg Gluz, Daniel Hofmann, +3 authors, Nadia Harbeck.
Breast Care (Basel), 2014 Feb 20; 8(6). PMID: 24550749    Free PMC article.
Differential Expression of Key Signaling Proteins in MCF10 Cell Lines, a Human Breast Cancer Progression Model.
Jae Young So, Hong Jin Lee, +2 authors, Nanjoo Suh.
Mol Cell Pharmacol, 2012 Jan 01; 4(1). PMID: 24558516    Free PMC article.
Estrogen receptor-negative breast ductal carcinoma: clinicopathological features and MIB-1 (Ki-67) proliferative index association.
Noorasmaliza Mdpaiman, Siti Aishah Md Ali, +7 authors, Srijit Das.
PLoS One, 2014 Mar 04; 9(2). PMID: 24586570    Free PMC article.
Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients.
Nicholas P Tobin, Linda S Lindström, +3 authors, Kristian Wennmalm.
Mol Oncol, 2014 Mar 19; 8(3). PMID: 24630985    Free PMC article.
Adaptive designs for clinical trials assessing biomarker-guided treatment strategies.
J Wason, A Marshall, +2 authors, N Stallard.
Br J Cancer, 2014 Mar 29; 110(8). PMID: 24667651    Free PMC article.
Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657).
Elizabeth L Cureton, Christina Yau, +5 authors, Laura J Esserman.
Ann Surg Oncol, 2014 May 03; 21(9). PMID: 24788555    Free PMC article.
cDNA hybrid capture improves transcriptome analysis on low-input and archived samples.
Christopher R Cabanski, Vincent Magrini, +12 authors, Christopher A Maher.
J Mol Diagn, 2014 May 13; 16(4). PMID: 24814956    Free PMC article.
Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.
Woonyoung Choi, Bogdan Czerniak, +4 authors, David J McConkey.
Nat Rev Urol, 2014 Jun 25; 11(7). PMID: 24960601
Highly Cited. Review.
Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.
Laura Zanotti, Alberto Bottini, +2 authors, Maria Rosa Cappelletti.
Tumour Biol, 2014 Jul 23; 35(9). PMID: 25048969
Prediction of individual response to anticancer therapy: historical and future perspectives.
Florian T Unger, Irene Witte, Kerstin A David.
Cell Mol Life Sci, 2014 Nov 13; 72(4). PMID: 25387856    Free PMC article.
Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study.
D Balmativola, C Marchiò, +26 authors, A Sapino.
Breast Cancer Res Treat, 2014 Nov 15; 148(3). PMID: 25395316    Free PMC article.
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.
Hallie Wimberly, Jason R Brown, +7 authors, David L Rimm.
Cancer Immunol Res, 2014 Dec 21; 3(4). PMID: 25527356    Free PMC article.
Highly Cited.
Management of locally advanced breast cancer-perspectives and future directions.
Konstantinos Tryfonidis, Elzbieta Senkus, Maria J Cardoso, Fatima Cardoso.
Nat Rev Clin Oncol, 2015 Feb 11; 12(3). PMID: 25668732
Integrated analysis of DNA methylation, immunohistochemistry and mRNA expression, data identifies a methylation expression index (MEI) robustly associated with survival of ER-positive breast cancer patients.
Jonine D Figueroa, Howard Yang, +6 authors, Maxwell Lee.
Breast Cancer Res Treat, 2015 Mar 17; 150(2). PMID: 25773928    Free PMC article.
In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?
Xavier Pivot, Laura Mansi, +14 authors, Christian Villanueva.
Oncologist, 2015 Mar 22; 20(4). PMID: 25795632    Free PMC article.
Comprehensive molecular screening: from the RT-PCR to the RNA-seq.
Carlota Costa, Ana Giménez-Capitán, Niki Karachaliou, Rafael Rosell.
Transl Lung Cancer Res, 2013 Apr 01; 2(2). PMID: 25806219    Free PMC article.
Markers for the identification of late breast cancer recurrence.
Ivana Sestak, Jack Cuzick.
Breast Cancer Res, 2015 Apr 08; 17. PMID: 25848913    Free PMC article.
Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy.
Tari A King, Monica Morrow.
Nat Rev Clin Oncol, 2015 Apr 09; 12(6). PMID: 25850554
ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer.
Subha Madhavan, Yuriy Gusev, Salendra Singh, Rebecca B Riggins.
J Exp Clin Cancer Res, 2015 May 15; 34. PMID: 25971350    Free PMC article.
Gene profiling and circulating tumor cells as biomarker to prognostic of patients with locoregional breast cancer.
Renata K Kuniyoshi, Flávia de Sousa Gehrke, +6 authors, Auro Del Giglio.
Tumour Biol, 2015 May 16; 36(10). PMID: 25976504
International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).
Vito Amoroso, Daniele Generali, +30 authors, Alberto Bottini.
J Natl Cancer Inst Monogr, 2015 Jun 13; 2015(51). PMID: 26063896    Free PMC article.
Gene Expression Signatures Based on Variability can Robustly Predict Tumor Progression and Prognosis.
Wikum Dinalankara, Héctor Corrada Bravo.
Cancer Inform, 2015 Jun 17; 14. PMID: 26078586    Free PMC article.
Immune profiling in human breast cancer using high-sensitivity detection and analysis techniques.
Brendon J Coventry, Michael J Weightman, John Bradley, John M Skinner.
JRSM Open, 2015 Oct 16; 6(9). PMID: 26464809    Free PMC article.
Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques.
Joerg Heil, Sherko Kümmel, +10 authors, Gunter von Minckwitz.
Br J Cancer, 2015 Nov 12; 113(11). PMID: 26554654    Free PMC article.
Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.
Dennis C Sgroi, Judy-Anne W Chapman, +10 authors, Michael Pollak.
Breast Cancer Res, 2016 Jan 06; 18(1). PMID: 26728744    Free PMC article.
Comprehensive Histologic Scoring to Maximize the Predictability of Pathology-generated Equation of Breast Cancer Oncotype DX Recurrence Score.
Thaer Khoury, Xiao Huang, +3 authors, Mateusz Opyrchal.
Appl Immunohistochem Mol Morphol, 2016 Jan 26; 24(10). PMID: 26808126    Free PMC article.
Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
Gaurav Agarwal, Gitika Nanda, +4 authors, Narendra Krishnani.
World J Surg, 2016 Feb 05; 40(6). PMID: 26842691
Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems.
Anosheh Afghahi, Maya Mathur, +14 authors, Allison W Kurian.
J Oncol Pract, 2016 May 26; 12(6). PMID: 27221993    Free PMC article.
The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment.
Josee-Lyne Ethier, Eitan Amir.
Mol Diagn Ther, 2016 May 29; 20(4). PMID: 27235162
Biology and Management of Patients With Triple-Negative Breast Cancer.
Priyanka Sharma.
Oncologist, 2016 Jul 13; 21(9). PMID: 27401886    Free PMC article.
Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women.
Sarah M Bernhardt, Pallave Dasari, +3 authors, Wendy V Ingman.
Front Oncol, 2016 Nov 30; 6. PMID: 27896218    Free PMC article.
Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Hans-Peter Sinn, Andreas Schneeweiss, +9 authors, Frederik Marmé.
BMC Cancer, 2017 Feb 15; 17(1). PMID: 28193205    Free PMC article.
Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.
A Sheri, I E Smith, +3 authors, M Dowsett.
Breast Cancer Res Treat, 2017 Apr 28; 164(2). PMID: 28447240    Free PMC article.
A high-throughput method to detect RNA profiling by integration of RT-MLPA with next generation sequencing technology.
Jing Wang, Xue Yang, +5 authors, Jidong Gao.
Oncotarget, 2017 May 26; 8(28). PMID: 28545022    Free PMC article.
Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors.
Daniel J Farrugia, Alessandra Landmann, +13 authors, Rohit Bhargava.
Mod Pathol, 2017 May 27; 30(8). PMID: 28548119
Construction of an integrated gene regulatory network link to stress-related immune system in cattle.
Elham Behdani, Mohammad Reza Bakhtiarizadeh.
Genetica, 2017 Aug 22; 145(4-5). PMID: 28825201
Ancestry as a potential modifier of gene expression in breast tumors from Colombian women.
Silvia J Serrano-Gómez, María Carolina Sanabria-Salas, +7 authors, Jovanny Zabaleta.
PLoS One, 2017 Aug 24; 12(8). PMID: 28832682    Free PMC article.
Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay.
Sung Gwe Ahn, Soong June Bae, +4 authors, Joon Jeong.
PLoS One, 2017 Nov 09; 12(11). PMID: 29117208    Free PMC article.
Diffusion-weighted MRI characteristics associated with prognostic pathological factors and recurrence risk in invasive ER+/HER2- breast cancers.
Nita Amornsiripanitch, Vicky T Nguyen, +4 authors, Savannah C Partridge.
J Magn Reson Imaging, 2017 Nov 28; 48(1). PMID: 29178616    Free PMC article.
Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer.
Sung Gwe Ahn, Yoon Jin Cha, +3 authors, Joon Jeong.
BMC Cancer, 2018 Mar 27; 18(1). PMID: 29573739    Free PMC article.
Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer.
Frankie Ann Holmes, Beth A Hellerstedt, +11 authors, Joyce O'Shaughnessy.
Cancer Med, 2018 Mar 28; 7(6). PMID: 29582557    Free PMC article.
Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
Priyanka Sharma.
Curr Treat Options Oncol, 2018 Apr 16; 19(5). PMID: 29656345
Interleukin enhancer binding factor 2 is a prognostic biomarker for breast cancer that also predicts neoadjuvant chemotherapy responses.
Zining Jin, Lu Xu, +9 authors, Bo Chen.
Am J Transl Res, 2018 Jul 19; 10(6). PMID: 30018709    Free PMC article.
Neoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this Field.
Santiago Escrivá-de-Romaní, Miriam Arumí, Esther Zamora, Meritxell Bellet.
Breast Care (Basel), 2018 Oct 16; 13(4). PMID: 30319327    Free PMC article.
CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy.
Wilson Eduardo Furlan Matos Alves, Murilo Bonatelli, +7 authors, Céline Pinheiro.
BMC Cancer, 2019 Dec 05; 19(1). PMID: 31795962    Free PMC article.
Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Hatem Soliman, Susanne Wagner, +9 authors, William Gradishar.
Ann Surg Oncol, 2020 Jan 08; 27(3). PMID: 31907749    Free PMC article.
Subgrouping breast cancer patients based on immune evasion mechanisms unravels a high involvement of transforming growth factor-beta and decoy receptor 3.
Mayassa J Bou-Dargham, Yuhang Liu, Qing-Xiang Amy Sang, Jinfeng Zhang.
PLoS One, 2018 Dec 05; 13(12). PMID: 30513096    Free PMC article.
The Correlation of Magee EquationsTM and Oncotype DX® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer.
Atilla Soran, Kaori Tane, Efe Sezgin, Rohit Bhargava.
Eur J Breast Health, 2020 Apr 15; 16(2). PMID: 32285033    Free PMC article.
The Evaluation of Magee Equation 2 in Predicting Response and Outcome in Hormone Receptor-Positive and HER2-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Napat Saigosoom, Doonyapat Sa-Nguanraksa, +2 authors, Pornchai O-Charoenrat.
Cancer Manag Res, 2020 Apr 21; 12. PMID: 32308485    Free PMC article.
Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy.
Yanjun Hou, Hiroaki Nitta, +3 authors, Zaibo Li.
Clin Breast Cancer, 2017 Dec 05; 18(2). PMID: 29198959    Free PMC article.
Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor-Positive Breast Cancer.
Tarek M A Abdel-Fatah, Graham R Ball, +14 authors, Stephen Y T Chan.
JAMA Netw Open, 2020 Jul 08; 3(7). PMID: 32633764    Free PMC article.
The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review.
Sophie Gordon-Craig, Ruth M Parks, Kwok-Leung Cheung.
Oncol Ther, 2020 Jul 24; 8(2). PMID: 32700048    Free PMC article.
Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy.
Yanding Zhao, Evelien Schaafsma, Chao Cheng.
Cancer Med, 2020 Jul 22; 9(17). PMID: 32692484    Free PMC article.
Ki-67 index value and progesterone receptor status can predict prognosis and suitable treatment in node-negative breast cancer patients with estrogen receptor-positive and HER2-negative tumors.
Nobuyuki Arima, Reiki Nishimura, +5 authors, Yasuo Toyozumi.
Oncol Lett, 2019 Jan 19; 17(1). PMID: 30655808    Free PMC article.
LncRNA Profile Study Reveals a Three-LncRNA Signature Associated With the Pathological Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer.
Ying Zeng, Guo Wang, +6 authors, Yuan-Shan Zhu.
Front Pharmacol, 2019 Jun 14; 10. PMID: 31191314    Free PMC article.
Molecular characterization of breast cancer needle core biopsy specimens by the 21-gene Breast Recurrence Score test.
Debbie M Jakubowski, Helen Bailey, +7 authors, Frederick L Baehner.
J Surg Oncol, 2020 Jun 05;. PMID: 32497318    Free PMC article.
Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach.
Jennifer Y Sheng, Cesar A Santa-Maria, +18 authors, Karen L Smith.
JCO Oncol Pract, 2020 Jul 01; 16(10). PMID: 32603252    Free PMC article.
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Hiroji Iwata, Norikazu Masuda, +19 authors, Yasuo Ohashi.
Breast Cancer Res Treat, 2018 Sep 23; 173(1). PMID: 30242578    Free PMC article.
Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study.
Rohit Bhargava, Nicole N Esposito, +11 authors, David J Dabbs.
Mod Pathol, 2020 Jul 15; 34(1). PMID: 32661297
The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients.
Xian Wu, Chaoran Ye, +7 authors, Xiaoan Liu.
Cancer Manag Res, 2021 Feb 25; 13. PMID: 33623431    Free PMC article.
Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art.
Florence Lerebours, Luc Cabel, Jean-Yves Pierga.
Cancers (Basel), 2021 Mar 07; 13(4). PMID: 33670042    Free PMC article.
Association between the nucleosome footprint of plasma DNA and neoadjuvant chemotherapy response for breast cancer.
Xu Yang, Geng-Xi Cai, +8 authors, Xue-Xi Yang.
NPJ Breast Cancer, 2021 Mar 28; 7(1). PMID: 33772032    Free PMC article.
Isochromanoindolenines suppress triple-negative breast cancer cell proliferation partially via inhibiting Akt activation.
Xiaoyan Jiang, Xu Zhi, +8 authors, Ceshi Chen.
Int J Biol Sci, 2021 Apr 20; 17(4). PMID: 33867823    Free PMC article.